Eef Schimmelpennink, Lenz Therapeutics CEO
March 22, 2024 02:17 PM EDT
People
Financing

Why Lenz picked a re­verse merg­er in­stead of an IPO: Q&A

Kyle LaHucik

Senior Reporter

Fol­low­ing Lenz Ther­a­peu­tics’ de­but on the Nas­daq Fri­day, End­points News spoke with CEO Eef Schim­melpen­nink about the think­ing be­hind

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Arc In­sti­tute pub­lish­es new AI mod­el Evo, cre­at­ing CRISPR sys­tems in a leap for syn­thet­ic bi­ol­o­gy

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times